Sofosbuvir in the treatment of early HCV infection in HIV-infected men

References

• Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345(20):1452–1457.10.1056/NEJMoa011232
   PubMed Web of Science ®Google Scholar
• Ghosn J, Pierre-Francois S, Thibault V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med. 2004;5(4):303–306.10.1111/hiv.2004.5.issue-4
   PubMed Web of Science ®Google Scholar
• Götz HM, van Doornum G, Niesters HG, et al. A cluster of acute hepatitis C virus infection among men who have sex with men–results from contact tracing and public health implications. AIDS. 2005;19(9):969–974.10.1097/01.aids.0000171412.61360.f8
   PubMed Web of Science ®Google Scholar
• Gilleece YC, Browne RE, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005;40(1):41–46.10.1097/01.qai.0000174930.64145.a9
   PubMed Web of Science ®Google Scholar
• Vogel M, Bieniek B, Jessen H, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat. 2005;12(2):207–211.10.1111/jvh.2005.12.issue-2
   PubMed Web of Science ®Google Scholar
• Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41(1):31–36.10.1097/01.qai.0000191281.77954.27
   PubMed Web of Science ®Google Scholar
• Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis. 2008;198(5):683–686.10.1086/592362
   PubMed Web of Science ®Google Scholar
• Bottieau E, Apers L, Van Esbroeck M, et al. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001–2009. Euro Surveill. 2010;15(39):19673.
   PubMedGoogle Scholar
• Barfod TS, Omland LH, Katzenstein TL. Incidence and characteristics of sexually transmitted acute hepatitis C virus infection among HIV-positive men who have sex with men in Copenhagen, Denmark during four years (2006–2009): a retrospective cohort study. Scand J Infect Dis. 2011;43(2):145–148.10.3109/00365548.2010.524660
   PubMed Web of Science ®Google Scholar
• Sun HY, Chang SY, Yang ZY, et al. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol. 2012;50(3):781–787.10.1128/JCM.06014-11
   PubMed Web of Science ®Google Scholar
• Ishikane M, Watanabe K, Tsukada K, et al. Acute hepatitis C in HIV-1 infected Japanese cohort: single center retrospective cohort study. PLoS ONE. 2014;9(6):e100517.10.1371/journal.pone.0100517
   PubMed Web of Science ®Google Scholar
• Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20(8):1157–1161.10.1097/01.aids.0000226956.02719.fd
   PubMed Web of Science ®Google Scholar
• Vogel M, Nattermann J, Baumgarten A, et al. Pegylated interferon-alfa for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther. 2006;11(8):1097–1101.
   PubMed Web of Science ®Google Scholar
• Matthews GV, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C. Clin Infect Dis. 2009;48(5):650–658.10.1086/597768
   PubMed Web of Science ®Google Scholar
• Piroth L, Larsen C, Binquet C, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology. 2010;52(6):1915–1921.10.1002/hep.23959
   PubMed Web of Science ®Google Scholar
• Lambers FA, Brinkman K, Schinkel J, et al. Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. AIDS. 2011;25(10):1333–1336.10.1097/QAD.0b013e3283480144
   PubMed Web of Science ®Google Scholar
• Obermeier M, Ingiliz P, Weitner L, et al. Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the “real-life setting” proves the concept. Eur J Med Res. 2011;16(5):237–242.10.1186/2047-783X-16-5-237
   PubMed Web of Science ®Google Scholar
• Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2011;60(6):837–845.10.1136/gut.2010.217166
   PubMed Web of Science ®Google Scholar
• Garg S, Taylor LE, Grasso C, et al. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis. 2013;56(10):1480–1487.10.1093/cid/cit054
   PubMed Web of Science ®Google Scholar
• Webster DP, Wojcikiewicz T, Keller M, et al. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin. Int J STD AIDS. 2013;24(3):179–183.10.1177/0956462412472317
   PubMed Web of Science ®Google Scholar
• Fierer DS, Dieterich DT, Mullen MP, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014;58(6):873–879.10.1093/cid/cit799
   PubMed Web of Science ®Google Scholar
• Fierer DS, Dieterich DT, Mullen MP, et al. Telaprevir in the treatment of acute HCV infection in HIV-infected Men: final results. American Association for the Study of Liver Disease. Poster 1112. Boston, MA, 15 February 2015.
   Google Scholar
• Hullegie SJ, Claassen MA, van den Berk GE, et al. Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. J Hepatol. 2016;64(4):807–812.10.1016/j.jhep.2015.12.004
   PubMed Web of Science ®Google Scholar
• Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics. JAMA. 2013;310(8):804–811.10.1001/jama.2013.109309
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353–361.10.1001/jama.2014.7734
   PubMed Web of Science ®Google Scholar
• Fierer DS, Factor SH, Uriel AJ, et al. Sexual transmission of hepatitis C virus (HCV) among HIV-infected men who have sex with men (MSM), New York City, 2005–2010. MMWR Morb Mortal Wkly Rep. 2011;60(28):945–950.
   PubMedGoogle Scholar
• Fierer DS, Mullen MP, Dieterich DT, et al. Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men. Clin Infect Dis. 2012;55(6):887–888.10.1093/cid/cis538
   PubMed Web of Science ®Google Scholar
• Fierer DS, Dieterich DT, Fiel MI, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis. 2013;56(7):1038–1043.10.1093/cid/cis1206
   PubMed Web of Science ®Google Scholar
• Turner SS, Gianella S, Yip MJ-S, et al. Shedding of hepatitis C virus in semen of HIV-infected men. Open Forum Infect Dis. 2016;3(2). ofw057.
   Web of Science ®Google Scholar
• Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin Liver Dis. 2005;25(1):7–17.10.1055/s-2005-864778
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86–96.
   PubMed Web of Science ®Google Scholar
• Naggie S, Marks KM, Hughes M, et al. Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1 infected individuals (SWIFT-C). American Association for the Study of Liver Disease. Abstract 1094. Boston, MA, 15 November 2015.
   Google Scholar
• Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon Alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451–459.
   PubMed Web of Science ®Google Scholar
• MacBrayne CE, Hughes M, Hollabaugh KM, et al. Lower ribavirin exposures in HIV+ patients that relapsed to acute HCV treatment. Conference on Retroviruses and Opportunistic Infections. Abstract 99. Boston, MA, 15 February 2016.
   Google Scholar
• Taylor LE, Fierer DS. Treatment of early hepatitis C infection in HIV-infected men – when to treat, whom, and with what? Curr Treat Options Infect Dis. e-pub. 10 October 2016.
   Google Scholar
• Martinello M, Gane EJ, Hellard M, et al. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: the DARE-C II study. Hepatology. epub 17 September 2016.
   PubMed Web of Science ®Google Scholar
• Basu P, Shah NJ, John N, et al. Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir combination therapy in the management of acute hepatitis C: a randomized open label prospective clinical pilot study. SLAM C study. Interim data. American Association for the Study of Liver Disease (AASLD). Abstract 1074. Boston, MA, 15 November 2015.
   Google Scholar
• Rockstroh JK, Bhagani S, Hyland RH, et al. Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection. Conference on Retroviruses and Opportunistic Infections. Abstract 154LB. Boston, MA, 25 February, 2016.
   Google Scholar
• AASLD-IDSA. Management of acute HCV infection. Recommended treatment for Patients with acute HCV infection. Accessed 24 July 2016. http://hcvguidelines.org/full-report/management-acute-hcv-infection.
   Google Scholar
• Calleri G, Cariti G, Gaiottino F, et al. A short course of pegylated interferon-alfa in acute HCV hepatitis. J Viral Hepat. 2007;14(2):116–121.10.1111/jvh.2007.14.issue-2
   PubMed Web of Science ®Google Scholar
• Kaplan-Lewis E, Fierer DS. Acute HCV in HIV-Infected MSM: modes of acquisition, liver Fibrosis, and treatment. Curr HIV/AIDS Rep. 2015;12(3):317–325.10.1007/s11904-015-0279-3
   PubMed Web of Science ®Google Scholar
• Barua S, Greenwald R, Grebely J, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C Virus infection in the United States. Ann Intern Med. 2015;163(3):215–223.10.7326/M15-0406
   PubMed Web of Science ®Google Scholar
• HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated 28 January 2016. Accessed 1 May 2016. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0.
   Google Scholar
• Martin NK, Thornton A, Hickman M, et al. Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights. Clin Infect Dis. 2016;62(9):1072–1080.10.1093/cid/ciw075
   PubMed Web of Science ®Google Scholar